Evaluation Targeting EGFR Exon-20 Insertion Mutations in Non-Small Cell Lung Cancer Evaluation HMP Education would appreciate your feedback on the quality and impact of this activity.Please answer the following questions, some of which include a 5-point Likert scale (5 = strongly agree/excellent/great deal; 1 = strongly disagree/poor/very little). Did this activity meet your educational needs? Yes No Did this activity increase your competence? Yes No Do you feel like there were any new data presented during this activity? Yes - please explain: No Did you learn anything new? Yes, please specify: No Did you gain confidence in your ability to act on the new information? Yes - please explain: No Did this activity include opportunities to learn as a part of a healthcare team? Yes - please explain: No Please answer the following question using a 5-point likert scale (5 = a great deal, 3 = a modest amount, 1 = nothing at all). How much did you learn as a result of this session? 5 4 3 2 1 Please rate the following components related to this activity using a 5-point likert scale (5 = excellent, 3 = good, 1 = poor). Content 5 4 3 2 1 Relevance to your practice 5 4 3 2 1 Educational format 5 4 3 2 1 Overall 5 4 3 2 1 Please rate the faculty on their knowledge, expertise, and teaching ability (5= excellent, 3 = good, 1 = poor). Jonathan Goldman, MD 5 4 3 2 1 Corey Langer, MD, FACP 5 4 3 2 1 To what extent were the following learning objectives addressed by this activity (5 = entirely, 3 = moderately, 1 = not at all)? Summarize the impact of EGFR exon 20 insertion mutations on patients with NSCLC, including patient outcomes and molecular testing modalities 5 4 3 2 1 Evaluate current clinical data concerning the efficacy, safety, and sequencing of EGFR exon 20 insertion-targeted therapies 5 4 3 2 1 Recognize treatment-related adverse events and incorporate strategies to anticipate and mitigate adverse events associated with EGFR exon 20 insertion-targeted therapies in NSCLC to minimize treatment interruptions 5 4 3 2 1 The information presented in this activity was free of commercial bias. Agree Disagree How many patients do you encounter with NSCLC on a monthly basis? 10 or fewer 20 30 40 50 or more Please now rate your ability to use currently available therapies to manage NSCLC. Excellent Very Good Good Fair Poor Do you intend to make any changes to your practice as a result of information gained from this activity? Please be specific. Yes, please describe: No Which of the following barriers do you perceive in your efforts to implement practice changes and/or optimize patient care? Select all that apply. No barriers Cost Lack of opportunity/patients Lack of administrative support Insurance/reimbursement issues Lack of consensus or professional guidelines Lack of time to assess/counsel patients Patient compliance issues Not applicable to my practice Other: How might future activities help you address those barriers? 255 characters max Which of the following statements is TRUE regarding PCR-based molecular testing in EGFR exon 20 insertion? Exon 20 insertions can be detected with a selectivity of 0.01% and sensitivity as low as a single copy. Nearly 60% of patients remain untested for EGFR mutations. NCCN guidelines recommend against liquid biopsy. The specific sequence of EGFR ex20ins mutations is required. Updated CHRYSALIS data presented at the European Lung Cancer Congress in April 2023, which of the following agents was shown to have a median OS of 23 months and an ORR of 37% in patients with EGFR ex20ins-positive NSCLC after progression on platinum-based chemotherapy? Amivantamab Mobocertinib Osimertinib Poziotinib Which of the following is the most common grade 3-4 adverse event associated with EGFR exon-20 tyrosine kinase inhibitors treatment for NSCLC? Diarrhea Hypoalbuminemia Infusion-related reactions QTc prolongation Please now rate your ability to distinguish among newer therapeutic options for the management of EGFR ex20ins-positive NSCLC. Excellent Very Good Good Fair Poor As a result of this activity, I intend to make changes in the following areas as they pertain to the management of NSCLC (select all that apply): Implement strategies to help overcome common barriers to care, including appropriate molecular testing for EGFR mutations and adverse event management Recommend newer agents that have been found to improve ORR in patients with EGFR ex20ins-positive NSCLC Make informed recommendations for therapies based on individual patient profiles and the latest available clinical evidence Develop patient-centered management plans that underscore the importance of shared decision-making and patient activation as a major component of successful treatment for EGFR ex20ins-positive NSCLC Integrate evidence-based guidelines for the management of EGFR ex20ins-positive NSCLC while supporting the translation of clinical evidence to practice Apply concepts that support the translation of clinical evidence to practice Other (please specify): Previous
